These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 21029596)

  • 1. [Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
    Li Y; Weng DH; Kong FF; Fan LS; Hu Y; Song XH; Xing H; Wang W; Ma D; Wang SX
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jun; 45(6):445-8. PubMed ID: 21029596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
    Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
    Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Frankel A; Man S; Elliott P; Adams J; Kerbel RS
    Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
    Fang Y; Hu Y; Wu P; Wang B; Tian Y; Xia X; Zhang Q; Chen T; Jiang X; Ma Q; Xu G; Wang S; Zhou J; Ma D; Meng L
    Cancer Invest; 2011 May; 29(4):247-52. PubMed ID: 21345073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
    Yang BF; Xiao C; Li H; Yang SJ
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
    Abedini MR; Muller EJ; Brun J; Bergeron R; Gray DA; Tsang BK
    Cancer Res; 2008 Jun; 68(12):4511-7. PubMed ID: 18559494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
    Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
    Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
    Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
    Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis].
    Weng DH; Li Y; Kong FF; Fan LS; Hu Y; Song XH; Xing H; Wang SX; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):770-3. PubMed ID: 19087546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
    Sorolla A; Yeramian A; Dolcet X; Pérez de Santos AM; Llobet D; Schoenenberger JA; Casanova JM; Soria X; Egido R; Llombart A; Vilella R; Matias-Guiu X; Marti RM
    Br J Dermatol; 2008 Mar; 158(3):496-504. PubMed ID: 18205878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells.
    Pak JH; Choi WH; Lee HM; Joo WD; Kim JH; Kim YT; Kim YM; Nam JH
    Cancer Invest; 2011 Jan; 29(1):21-8. PubMed ID: 21166495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
    Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
    Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.
    Abedini MR; Qiu Q; Yan X; Tsang BK
    Oncogene; 2004 Sep; 23(42):6997-7004. PubMed ID: 15258564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.